1421 ET - Hims & Hers Health has ample opportunities to grow its weight-loss offerings even after GLP-1 drugs are taken off the FDA's shortage list, TD Cowen analysts say in a research note after meeting with management. A key concern for the stock is how the weight-loss platform will grow in a world if Hims can no longer offer compounded GLP-1s, the analysts say. But management believes it can provide a variety of weight loss offerings, including oral medication, personalized dosages of compounded GLP-1s, branded GLP-1s and liraglutide, that will ultimately be more affordable than a traditional GLP-1 program, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
November 08, 2024 14:21 ET (19:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.